metaEvidence - overview

benefit
(statisticaly significant)

benefit (nominaly significant, not statitically demonstrated)

not significant

harm statitically significant

harm not significant

low certainty due to bias


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
mML - NA - all population metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - all population
versus interferon alpha
	Ipilimumab (10 mg/kg) vs. interferon alpha	1		-
	ipilimumab alone vs. interferon alpha	1		-
versus placebo
	Ipilimumab (10 mg/kg) vs. placebo	1		-
mML - NA - PDL1 positive metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - PDL1 positive
mML - L1 - all population metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - all population
mML - L1 - BRAF mutant metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF mutant
mML - L1 - BRAF wild metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF wild
mML - L2 - all population metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - all population
versus gp100
	ipilimumab alone vs. gp100	1		-	-
	ipilimumab plus gp100 vs. gp100	1		-	-
versus ipilimumab alone
	Ipilimumab (10 mg/kg) vs. ipilimumab alone	1			-
	ipilimumab plus gp100 vs. ipilimumab alone	1		-	-
versus placebo plus SoC
	ipilimumab plus SoC vs. placebo plus SoC	1			-
mML - L2 - BRAF mutant metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - BRAF mutant